TNBC Education
Triple-negative breast cancer has seen transformative advances with immunotherapy combinations and antibody-drug conjugates. Knowledge Med sessions help community providers apply emerging data to practice through interactive case simulations — from PD-L1 testing and immunotherapy selection to ADC sequencing and BRCA-directed therapy.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing triple-negative breast cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting patients for immunotherapy based on PD-L1 expression
- Sequencing checkpoint inhibitors, ADCs, and PARP inhibitors
- Identifying BRCA1/2 and other actionable genomic alterations
- Managing immune-related adverse events in combination regimens
What Sessions Cover
Knowledge Med TNBC sessions use interactive case simulations to address these topics and more.
- Immunotherapy in first-line metastatic TNBC: patient selection and regimens
- Antibody-drug conjugates: sacituzumab govitecan and emerging agents
- PARP inhibitor use in BRCA-mutated TNBC
- Biomarker-driven treatment algorithms for metastatic TNBC
Interactive TNBC Sessions
Case Simulations
Work through realistic triple-negative breast cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key TNBC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Non-Small Cell Lung Cancer
NSCLC — Biomarker-driven first-line therapy selection in advanced NSCLC
Join a TNBC Session
Third-party, non-promotional triple-negative breast cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session